CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.2646
-0.0119 (-4.30%)
Sep 26, 2025, 3:59 PM EDT
CytoDyn Employees
CytoDyn had 13 employees as of May 31, 2025. The number of employees increased by 4 or 44.44% compared to the previous year.
Employees
13
Change (1Y)
4
Growth (1Y)
44.44%
Revenue / Employee
n/a
Profits / Employee
$174,000
Market Cap
332.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Jushi Holdings | 1,234 |
CytoDyn News
- 3 days ago - CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity - GlobeNewsWire
- 12 days ago - CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity - GlobeNewsWire
- 24 days ago - CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - CytoDyn files $100M mixed securities shelf - Seeking Alpha
- 3 months ago - CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab - GlobeNewsWire
- 3 months ago - CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer - GlobeNewsWire
- 4 months ago - A Penny Stock To Watch In Challenging Cancer Space - Benzinga